LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report)'s stock price fell 4.1% during mid-day trading on Friday . The company traded as low as $29.05 and last traded at $29.05. 20,626 shares traded hands during mid-day trading, a decline of 85% from the average session volume of 135,238 shares. The stock had previously closed at $30.28.
Analysts Set New Price Targets
Several brokerages recently weighed in on LENZ. William Blair raised LENZ Therapeutics to a "strong-buy" rating in a report on Friday, August 30th. Raymond James assumed coverage on shares of LENZ Therapeutics in a research note on Friday, September 27th. They issued an "outperform" rating and a $37.00 target price for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $38.00 price target on shares of LENZ Therapeutics in a research note on Thursday, November 7th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $35.40.
View Our Latest Research Report on LENZ Therapeutics
LENZ Therapeutics Price Performance
The business has a fifty day simple moving average of $31.60 and a 200 day simple moving average of $24.87.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.09. During the same quarter last year, the firm posted ($1.33) earnings per share. Equities research analysts expect that LENZ Therapeutics, Inc. will post -2.09 EPS for the current year.
Institutional Investors Weigh In On LENZ Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC purchased a new stake in LENZ Therapeutics during the third quarter worth $107,000. MetLife Investment Management LLC acquired a new position in shares of LENZ Therapeutics during the 3rd quarter worth $182,000. GSA Capital Partners LLP purchased a new stake in shares of LENZ Therapeutics in the 3rd quarter worth about $246,000. Squarepoint Ops LLC acquired a new stake in LENZ Therapeutics in the 2nd quarter valued at about $181,000. Finally, Jane Street Group LLC purchased a new position in LENZ Therapeutics during the 3rd quarter valued at about $286,000. Institutional investors and hedge funds own 54.32% of the company's stock.
About LENZ Therapeutics
(
Get Free Report)
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Further Reading
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
